Cardiac toxicity in the radiation treatment of esophageal cancer: An emerging concern

Future Cardiology

Volumn 11, Issue 4, 2015, Pages 367-369

  Beukema, Jannet C ^a   Langendijk, Johannes A ^a   Muijs, Christina T ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Cardiac toxicity; Esophageal cancer; Radiotherapy

Indexed keywords

ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RISK; CARDIOTOXICITY; CHEMORADIOTHERAPY; EDITORIAL; ESOPHAGUS CANCER; HUMAN; PRIORITY JOURNAL; PROTON THERAPY; RISK ASSESSMENT; TREATMENT OUTCOME; ADVERSE EFFECTS; ESOPHAGEAL NEOPLASMS; HEART DISEASES;

CARDIOTOXICITY; CHEMORADIOTHERAPY; ESOPHAGEAL NEOPLASMS; HEART DISEASES; HUMANS;

EID: 84939426316     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/FCA.15.44     Document Type: Editorial

References (13)

1. Van Hagen P, Hulshof MCCM, van Lanschot JJB et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N. Engl. J. Med. 366(22), 2074-2084 (2012).
2. Pöttgen C, Stuschke M. Radiotherapy versus surgery within multimodality protocols for esophageal cancer-a meta-analysis of the randomized trials. Cancer Treat. Rev. 38, 599-604 (2012).
3. Aleman BMP, van den Belt-Dusebout AW, Klokman WJ, Van't Veer MB, Bartelink H, van Leeuwen FE. Long-term cause-specific mortality of patients treated for Hodgkin's disease. J. Clin. Oncol. 21(18), 3431-3439 (2003).
4. McGale P, Darby SC, Hall P et al. Incidence of heart disease in 35,000 women treated with radiotherapy for breast cancer in Denmark and Sweden. Radiother. Oncol. 100(2), 167-175 (2011).
5. Darby SC, Ewertz M, McGale P et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N. Engl. J. Med. 368(11), 987-998 (2013).
6. Beukema JC, van Luijk P, Widder J, Langendijk JA, Muijs CT. Is cardiac toxicity a relevant issue in the radiation treatment of esophageal cancer? Radiother. Oncol. 114, 85-90 (2015).
7. Stewart F A. Mechanisms and dose-response relationships for radiation-induced cardiovascular disease. Ann. ICRP 41(3-4), 72-79 (2011).
8. Fukada J, Shigematsu N, Takeuchi H. Symptomatic pericardial effusion after chemoradiation therapy in esophageal cancer patients. Radiat. Oncol. Biol. 87(3), 487-493 (2013).
9. Konski A, Li T, Christensen M et al. Symptomatic cardiac toxicity is predicted by dosimetric and patient factors rather than changes in 18F-FDG PET determination of myocardial activity after chemoradiotherapy for esophageal cancer. Radiother. Oncol. 104(1), 72-77 (2012).
10. Kole TP, Aghayere O, Kwah J, Yorke ED, Goodman KA. Comparison of heart and coronary artery doses associated with intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy for distal esophageal cancer. Int. J. Radiat. Oncol. Biol. Phys. 83(5), 1580-1586 (2012).
11. Ordu AD, Nieder C, Geinitz H et al. Association between radiation dose and pathological complete response after preoperative radiochemotherapy in esophageal squamous cell cancer. Anticancer Res. 34, 7255-7261 (2014).
12. Welsh J, Gomez D, Palmer MB et al. Intensity-modulated proton therapy further reduces normal tissue exposure during definitive therapy for locally advanced distal esophageal tumors: A dosimetric study. Int. J. Radiat. Oncol. Biol. Phys. 81(5), 1336-1342 (2011).
13. Langendijk JA, Lambin P, De Ruysscher D, Widder J, Bos M, Verheij M. Selection of patients for radiotherapy with protons aiming at reduction of side effects: the model-based approach. Radiother. Oncol. 107(3), 267-273 (2013).